CYP 3.85% 25.0¢ cynata therapeutics limited

Ann: Quarterly Activity Report & Appendix 4C, page-2

  1. 17,528 Posts.
    lightbulb Created with Sketch. 422
    "The board and management continue to actively engage with strategic parties and potential partners and will assess opportunities as they arise, with interest received in several indications. Cynata seeks to strengthen its commercialisation strategy by advancing clinical development and undertaking further corporate partnering transactions."

    I seem to read something along these lines in the last number of quarterlies
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.